Swarm Oncology Partners with Cellex to Advance T Cell Therapy for Solid Tumours

• Swarm Oncology has partnered with Cellex Cell Professionals GmbH to support the development and manufacturing of its novel T cell therapy, Swarm-T.

• The collaboration will enable GMP manufacturing, quality control, and regulatory compliance support to accelerate clinical trials planned for 2026.

Swarm Oncology Ltd. has announced a strategic partnership with Cellex Cell Professionals GmbH, a CDMO specialising in cell and gene therapy manufacturing. The collaboration aims to accelerate the development of Swarm’s novel T cell therapy platform, Swarm-T, which is designed to achieve long-term remission in patients with advanced solid cancers.

Despite advancements in oncology, over 82% of patients with metastatic cancer eventually succumb to the disease. Current immunotherapies face challenges such as T cell exhaustion, limited antigen diversity, and inadequate cell numbers. Swarm-T addresses these limitations by integrating in vivo immune priming with proprietary ex vivo manufacturing, generating potent, non-exhausted, polyclonal T cells to deliver a sustained immune attack against solid tumours.

As part of the partnership, Cellex will supply cellular starting material, oversee process transfer, and provide GMP manufacturing and quality control. Additionally, Cellex will offer regulatory compliance support and specialised infrastructure to streamline clinical development, aiming to initiate clinical trials in 2026.

“Swarm’s mission is to transform immunotherapy by overcoming its limitations and driving solid cancers into long-term remission,” said Martin Olin, CEO of Swarm Oncology. “With Cellex’s deep expertise in cell collection, therapy manufacturing, and regulatory compliance, we can ensure a seamless, high-quality manufacturing process and advance clinical development.”

Cellex, with over a decade of experience in T cell therapy manufacturing, will provide the scalability required to bring Swarm-T to clinical trials efficiently. Prof. Dr. Gerhard Ehninger, CEO of Cellex, added: “With our specialised infrastructure and experience, we are well-positioned to help bring these transformative therapies to the clinic faster and more efficiently.”